Flputnam Investment Management Co. Has $17.69 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Flputnam Investment Management Co. increased its stake in Vertex Pharmaceuticals by 16.1%, acquiring a total of 36,496 shares valued at approximately $17.69 million.
• Vertex Pharmaceuticals reported an earnings per share (EPS) of $4.52 for the last quarter, exceeding analysts' expectations of $4.24, with a revenue increase of 11.3% year-over-year.
• The company has a consensus target price of $497.10, with a majority of analysts rating the stock as a "Moderate Buy".

Flputnam Investment Management Co. grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 16.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,496 shares of the pharmaceutical company's stock after buying an additional 5,053 shares during the period. Flputnam Investment Management Co.'s holdings in Vertex Pharmaceuticals were worth $17,694,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Activest Wealth Management bought a new position in Vertex Pharmaceuticals during the 1st quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 45 shares during the period. Mascagni Wealth Management Inc. bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at $31,000. Mpwm Advisory Solutions LLC bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $40,000. Finally, Minot DeBlois Advisors LLC bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $44,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $391.02 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88. The firm has a market capitalization of $100.25 billion, a PE ratio of 27.95 and a beta of 0.44. The company has a 50-day simple moving average of $433.35 and a two-hundred day simple moving average of $458.70.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter in the previous year, the firm posted ($12.83) EPS. The firm's revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Activity

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on VRTX shares. UBS Group set a $553.00 price objective on Vertex Pharmaceuticals and gave the company a "buy" rating in a research note on Tuesday, August 5th. Scotiabank decreased their price objective on Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating for the company in a report on Tuesday, August 5th. Cantor Fitzgerald dropped their price objective on Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 5th. HC Wainwright dropped their target price on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating on the stock in a research report on Tuesday, August 5th. Finally, Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and thirteen have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $497.10.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.